TScan Therapeutics
a clinical-stage biotechnology company building a TCR discovery and TCR-T treatment platform, reporting first-quarter 2026 financials in May 2026; it identifies tumour-specific targets via T-cell receptor sequencing.
- Country
- United States
- Ticker
- TCRX
TCR-T discovery platform
Coverage
| CN | EU | US | |
|---|---|---|---|
| therapeutics-platforms | ✓ | ✓ | ✓ |
Regulatorsfdaemanmpa
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| TCR therapy (T-cell receptor engineered T cells) | therapeutics-platforms | Low | → |
Compiled by BIOECON via the bioecon-brief pipeline.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.